Ignite Creation Date:
2024-05-06 @ 8:17 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06323382
Status:
RECRUITING
Last Update Posted:
2024-03-21
First Post:
2024-03-15
Brief Title:
Locoregional Therapy Combined With Bevacizumab and PD1L1 Inhibitor in Advanced Hepatocellular Carcinoma
Sponsor:
Sun Yat-sen University
Organization:
Sun Yat-sen University
Study Overview
Official Title:
Efficacy of Locoregional Therapy Combined With Bevacizumab and PD1L1 Inhibitor in Advanced Hepatocellular Carcinoma a Multicenter Observational Real-world Study
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Atezolizumab Bevacizumab was superior to sorafenib in overall survival in advanced hepatocellular carcinoma The programmed cell death protein-1 PD1 and PDL1 inhibitor was effective and tolerable in patients with advanced hepatocellular carcinoma We aimed to describe the efficacy and safety of locoregional therapy combined with Bevacizumab and PD1L1 inhibitor in patients with advanced hepatocellular carcinoma who can not receive radical therapy
Detailed Description:
This study is a multicenter observational real-world study to explore the efficacy safety of locoregional therapy combined with Bevacizumab and PD1L1 inhibitor in advanced hepatocellular carcinoma This study focused on the management of locoregional therapy combined with Bevacizumab and PD-1L1 inhibitor This study will create a database that will provide clinical parameters and outcomes of patients undergoing locoregional therapy combined Bevacizumab and PD-1L1 inhibitor as standard of care in hopes of answering key clinical questions
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None